Guest:
Dr. Bas Trietsch is the Chief Technology Officer and Co-Founder at Mimetas, a company working to contribute to groundbreaking therapies with their screenable, physiologically relevant 3D human disease models. He talks about tissue-relevant models for drug discovery, and how organ-on-a-chip technology can help address scalability and reproducibility.
Featured Products and Resources:
- Register for a live show in New York to discuss BlueRock Therapeutics’ stem cell-derived investigational cell therapy designed to treat patients with Parkinson’s disease.
- Learn about organoid culture from the experts at STEMCELL.
The Stem Cell Science Round Up
CRISPR Screens for Neurodevelopment Genes – Researchers integrated cortical assembloids with CRISPR screening to investigate genes implicated in neurodevelopmental disorders.
Metabolic Reprogramming for Heart Regeneration – Inhibiting fatty acid oxidation in cardiomyocytes stimulates cardiac regeneration in mice.
iPSC-Derived Cardiomyocyte and Endothelial Cell Transplants – hiPSC-derived endothelial cells and cardiomyocytes significantly enhanced graft size and vasculature and improved cardiac function after ischemic reperfusion in non-human primates.
A Bioengineered Trachea-Like Structure – A trachea-like structure composed of cartilage rings and fiber-hydrogel rings boosted survival after transplant into rabbits with a tracheal defect.
Photo Reference: Courtesy of Mimetas
Subscribe to our newsletter!
Never miss updates about new episodes.
Fler avsnitt av The Stem Cell Podcast
Visa alla avsnitt av The Stem Cell PodcastThe Stem Cell Podcast med The Stem Cell Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
